|
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Clinical research trials and Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer. Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer clinical trial. Subjects frequently get the best healthcare possible for their Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer  Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
For Condition: childhood kidney/urinary cancer,recurrent urethral cancer,recurrent transitional cell cancer of the renal pelvis and ureter,transitional cell carcinoma of the bladder,recurrent bladder cancer
Status: No longer recruiting
Sponsor(s): Medical Research Council ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fluorouracil given as a continuous infusion in treating patients with recurrent or metastatic bladder cancer.
Details: OBJECTIVES: I. Determine the response rate and toxic effects of continuous fluorouracil in patients with recurrent locally advanced or metastatic transitional cell urinary tract carcinoma. II. Determine the feasibility of this treatment in this patient population. PROTOCOL OUTLINE: Patients receive continuous intravenous fluorouracil by a Baxter Infusor for 24 weeks. Patients are evaluated for complete and partial response at 8, 16, and 24 weeks after the start of intravenous fluorouracil. Patients experiencing disease progression or unacceptable toxic effects are removed from the study. Patients are followed monthly for 6 months post treatment. PROJECTED ACCRUAL: A maximum of 45 patients will be accrued.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven recurrent locally advanced or metastatic transitional cell urinary tract carcinoma that has been previously untreated with systemic chemotherapy; Pelvic relapse after radiotherapy or surgery; No relapse solely within a previously irradiated field; Nodal or metastatic disease - Lesions within the abdomen or pelvis must be assessed using CT scanning - At least one site of disease must be previously unirradiated and assessable for response; Bone metastases cannot be used as an indicator lesion; Measurable disease --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior systemic chemotherapy - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics - Surgery: See Disease Characteristics --Patient Characteristics-- - Age: Not specified - Performance Status: Not specified - Life Expectancy: Not specified - Hematopoietic: WBC at least 3,500/mm3; Platelet count at least 100,000/mm3 - Hepatic: Not specified - Renal: Glomerular filtration rate at least 50 mL/min; Creatinine clearance at least 25 mL/min
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PeterHarper, Study Chair, Medical Research Council
Weston Park Hospital
Sheffield, England, S1O 2SJ
United Kingdom
University College Hospital
London, England, WC1E 6AU
United Kingdom
Maria Hospital
Helsinki, , FIN-0-0180
Finland
Royal Belfast Hospital for Sick Children
Belfast, Northern Ireland, BT12 6BE
United Kingdom
Christchurch Hospital
Christchurch, , 1
New Zealand
Royal Devon and Exeter Hospital
Exeter, England, EX2 5DW
United Kingdom
Middlesex Hospital- Meyerstein Institute
London, England, W1N 8AA
United Kingdom
Hopital Sainte Justine
Montreal, Quebec, H3T 1C5
Canada
Norwegian Radium Hospital
Oslo, , N-0310
Norway
South Tees Acute Hospitals NHS Trust
Middlesbrough, Cleveland, England, TS4 3BW
United Kingdom
Walsall Manor Hospital
Walsall, England, WS2 9PS
United Kingdom
Bristol Oncology Centre
Bristol, England, BS2 8ED
United Kingdom
University Birmingham
Birmingham, England, B15 2TT
United Kingdom
Cookridge Hospital
Leeds, England, LS16 6QB
United Kingdom
Ysbyty Gwynedd
Bangor, Wales,
United Kingdom
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Canada
Antoni van Leeuwenhoekhuis
Amsterdam, , 1066 CX
Netherlands
Bradford Hospitals NHS Trust
Bradford, England, BD9 6RJ
United Kingdom
Aberdeen Royal Infirmary
Aberdeen, Scotland, AB25 2ZN
United Kingdom
Norfolk & Norwich Hospital
Norwich, England, NR1 3SR
United Kingdom
Royal South Hants Hospital
Southampton, England, SO14 0YG
United Kingdom
Manchester Children's Hospitals (NHS Trust)
Manchester, England, M27 SHA
United Kingdom
Portsmouth Hospitals NHS Trust
Portsmouth, England, P03 6AD
United Kingdom
Mount Vernon Hospital
Northwood, England, HA6 2RN
United Kingdom
Derbyshire Royal Infirmary
Derby, England, DE1 2QY
United Kingdom
Oxford Radcliffe Hospital
Oxford, England, 0X3 7LJ
United Kingdom
Mount Sinai Hospital - Toronto
Toronto, Ontario, M5G 1X5
Canada
Royal Marsden Hospital
Sutton, England, SM2 5PT
United Kingdom
Bristol Royal Hospital for Sick Children
Bristol, England, BS2 8BJ
United Kingdom
Ninewells Hospital and Medical School
Dundee, Scotland, DD1 9SY
United Kingdom
Kent and Canterbury Hospital
Canterbury, England, CT2 7NR
United Kingdom
Groote Schuur Hospital, Cape Town
Cape Town, , 7925
South Africa
Derbyshire Children's Hospital
Derby, England, DE1 3BA
United Kingdom
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Canada
Addenbrooke's NHS Trust
Cambridge, England, CB2 2QQ
United Kingdom
Porto Alegre Hospital
Porto Alegre, Rio Grande do Sul, 90035--003
Brazil
University Hospitals of Leicester
Leicester, England, LE1 5WW
United Kingdom
Royal Surrey County Hospital
Guildford, England, GU2 5XX
United Kingdom
Royal United Hospital
Bath, England, BA1 3NG
United Kingdom
Children's Hospital - Sheffield
Sheffield, England, S10 2TH
United Kingdom
St. James's Hospital
Leeds, England, LS9 7TF
United Kingdom
Guy's, King's and St. Thomas' Hospitals Trust
London, England, SE1 7EH
United Kingdom
Huddersfield Royal Infirmary
Huddersfield, West Yorks, England, HD3 3EA
United Kingdom
Royal Free Hospital
Hampstead, London, England, NW3 2QG
United Kingdom
Beatson Oncology Centre
Glasgow, Scotland, G11 6NT
United Kingdom
Royal Preston Hospital
Preston, , PR2 9HT
United Kingdom
Royal Infirmary
Glasgow, Scotland, G4 0SF
United Kingdom
Walsgrave Hospital
Coventry, England, CV2 2DX
United Kingdom
Llandough Hospital
Penarth, Wales, CF6 1XX
United Kingdom
Western General Hospital
Edinburgh, Scotland, EH4 9NQ
United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, England, NE1 4LP
United Kingdom
Royal Sussex County Hospital
Brighton, England, BN2 5BE
United Kingdom
Princess Royal Hospital
Telford, England, TF6 6TF
United Kingdom
Clatterbridge Centre for Oncology NHS Trust
Merseyside, England, L63 4JY
United Kingdom
Newcastle General Hospital
Newcastle upon Tyne, England, NE4 6BE
United Kingdom
Westminster Hospital
London, England, SW1P 2AP
United Kingdom
Southend General Hospital
Westcliff-On-Sea, England,
United Kingdom
St. Bartholomew's Hospital
London, England, EC1A 7BE
United Kingdom
Children's Hospital - Birmingham UK
Birmingham, England, B16 8ET
United Kingdom
Royal Hospital for Sick Children
Edinburgh, Scotland,
United Kingdom
Gloucester Royal NHS Trust - Glouchester Royal Hospital
Gloucester, England, GL1 3NN
United Kingdom
Southampton General Hospital
Southampton, England, SO16 6YD
United Kingdom
Additional Information:
Study ID Numbers: CDR0000065985; MRC-BA10,EU-97029
Study Start Date: December 1997
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003175
Other Transitional Cell Carcinoma Of The Bladder Studies:
1. Eflornithine in Treating Patients With Bladder Cancer
2. Celecoxib in Treating Patients With Bladder Cancer
3. AD 32 Alone or With BCG Following Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
4. Tipifarnib in Treating Patients With Recurrent Bladder Cancer
5. Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
Related Studies:
Other transitional cell carcinoma of the bladder Clinical Trials
Other England Clinical Trials
Other Gloucester Clinical Trials
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
|
|
|
|
|
|
|
|
